Articles tagged with Translational Research
Pennington Biomedical researchers will present scientific findings and participate in expert discussions at ObesityWeek 2026, highlighting advances in obesity science and treatment. The institution will also contribute to educational and early-career programming.
The ISSCR Consortium brings together industry, academia, and regulatory experts to establish standards and develop tools for stem cell-based models. Takeda's membership aims to accelerate the adoption of human stem cell-derived models in drug discovery and development.
The University of Oxford and Boston Children's Hospital are establishing a genetic medicines hub to design, test, and accelerate genetic medicines for neurodevelopmental disorders. The hub will develop a scalable platform for antisense oligonucleotide therapies, improving efficiency and reducing duplication in the development of geneti...
The report identifies gaps in the region to turn more science into companies and therapies, highlighting the need for stronger industry relationships and visibility. The Midwest has exceptional science, but collaboration across institutions, investors, and industry is key to unlocking its potential.
The UVA Biotech Innovation Fund will support the SPARK Innovative Medicines program, helping to accelerate promising discoveries into new treatments and cures. The fund will provide long-term support for researchers to overcome the critical gap between discovery and clinical application.
The ISSCR has recognized five scientists with Poster Awards for their outstanding contributions to iPSC research, showcasing progress in the field. The award honorees are from Japan, Switzerland, and the US, and were recognized for their research in advancing the clinical applications of iPSC technology.
The AI tool, GenStrain, uses generative AI to learn from DENSE MRI scans and apply that knowledge to standard cine MRI scans, helping doctors choose the pacing therapy most likely to benefit individual patients. This could lead to better cardiac care and patient outcomes for the 6 million Americans living with heart failure.
Dr. Petter Bjornstad will lead Pennington Biomedical Research Center in advancing research in metabolic disease, with a focus on improving the health and well-being of Louisiana residents. He brings exceptional expertise in diabetes and kidney disease, with a vision to translate world-class science into better health outcomes.
The ISSCR 2029 Annual Meeting will take place in Kyoto, Japan, showcasing discoveries across stem cell science and regenerative medicine. The event will foster international collaboration and accelerate progress in the field, with a focus on Japan's scientific leadership.
Weaning stress causes broad transcriptional and translational remodeling in piglets, leading to increased translation efficiency of key inflammatory mediators. GC-rich codons and gut microbiota composition play a role in this process.
The ISSCR has launched a new CDMO Directory to support stem cell research and clinical translation. The directory connects researchers with contract development and manufacturing organizations, providing a centralized resource for exploring manufacturing capabilities.
The ISSCR symposium in Kyoto, Japan celebrates 20 years of iPSC discovery, exploring fundamental discoveries, clinical translation, and emerging stem cell therapies. The event highlights key findings from recent research, including advances in iPSC biology, genetic stability, and disease modeling.
A Johns Hopkins Medicine-led team will build an artificial intelligence model to identify protein misfolding for earlier disease detection and treatment. The goal is to generate tools and resources for clinicians and researchers to diagnose and intervene at earlier stages of neurodegenerative conditions.
UChicago Medicine launches a groundbreaking clinical trial testing a new personalized cell therapy for advanced solid tumors, including ovarian cancer and melanoma. The treatment uses specially engineered T-cell receptors to detect hidden cancer proteins, expanding the number of cancers that can be targeted.
Stem Cell Reports will be the official meeting journal for the Australasian Society for Stem Cell Research 2026 Annual Scientific Meeting. The journal will provide complimentary ISSCR memberships for selected researchers and host a co-branded webinar in 2027.
The International Society for Stem Cell Research (ISSCR) is now accepting abstract submissions and registrations for its 2027 Annual Meeting in San Francisco. The event will showcase groundbreaking discoveries and emerging technologies, including AI advancements and cell-based therapies.
Juvmo, a Parkinson's disease drug, has been approved by the FDA and offers a new treatment option for patients, potentially reducing side effects. The drug's unique mechanism of action provides relief from motor symptoms, and its approval marks a significant milestone in the research of UVA Health scientists.
Pharmaceutical products can become contaminated with microorganisms, posing serious health risks. Sterilization processes vary in time and cost, with heat sterilization and gamma irradiation being traditional methods. Aseptic processing and sterile filtration are also used to produce sterile drug products.
A multidisciplinary team will integrate existing data to develop a computational framework predicting how vaginal tissue changes in response to hormones. The project aims to identify relationships between hormone dynamics and tissue microstructure and mechanics, ultimately improving women's health outcomes.
The portal will support 35-40 university programs and centers nationwide, serving over 50 entities and facilitating connections between researchers, industry partners, and government representatives. NJIT's Center for Translational Research has already supported four startups and over 45 funded projects, including OppyAI and PFASolve.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A new analysis from Cure reveals that universities can engage with industry through four distinct pathways, with bottom-decile institutions outperforming top-ranked universities in commercialization and entrepreneurship. The study found that universities can build meaningful partnerships by leveraging their strengths in specific areas,...
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
The journal welcomes leading researchers with expertise in hematopoietic and muscle stem cell biology, advancing understanding of stem cell research in health and disease. Drs. Bonnet and Relaix bring significant breadth of expertise and commitment to rigorous science, enhancing Stem Cell Reports' impact.
The grant will build on TTUHSC's foundation in basic and translational research, expanding clinical engagement and implementation science. The university will engage communities to identify health priorities and develop sustainable solutions.
A new AI tool has been developed to predict treatment and survival outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy. The tool consistently outperformed standard clinical biomarkers, achieving high accuracy scores in predicting survival outcomes.
Child cancer groups are urging a concerted effort to tackle pediatric sarcomas, a rare and aggressive form of childhood cancer. The groups propose three key priorities to improve collaboration, data sharing, and clinical infrastructure to translate discoveries into effective treatments.
Researchers develop biodegradable nanobone material that activates body's own healing properties to regrow bone, reducing need for invasive procedures. The material generates 80% more new bone than a material control and activates a key bone-repair growth factor with 10 times the level achieved using conventional methods.
Researchers at the University of Münster have found that using biomarkers to identify high-risk patients can significantly reduce the risk of kidney damage after major surgery. The approach has great potential to help sepsis patients too, and the team is working to incorporate these findings into international guidelines for the treatm...
Francesca Filbey, Ph.D., joins Center for BrainHealth as Deputy Director of Research, focusing on advancing research priorities, strengthening collaborations, and expanding impact. With expertise in addictive disorders and a strong track record of scientific excellence, Filbey aims to accelerate brain health research and its applications.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
Researchers have created a high-resolution functional map of human immune cells, revealing intricate circuits that govern health and disease. The dataset provides a powerful framework for designing cancer immunotherapies and treating autoimmune conditions, and serves as a foundation for AI models of biology.
Txn1 mutant rats exhibit severe kidney deterioration, with hallmarks of human CKD, including oxidative stress, mitochondrial dysfunction, and inflammation. The study identifies a link between chronic thioredoxin deficiency and CKD progression, suggesting promising therapeutic approaches.
The 2026 Childhood Obesity Conference, 'Be the Reason Kids Greaux Healthy,' will explore strategies for preventing and treating childhood obesity, bringing together healthcare professionals, researchers, educators, and community leaders. The conference will feature keynotes, sessions, and poster presentations on emerging topics in pedi...
Critical Path Institute (C-Path) has achieved ISO/IEC 27001:2022 certification, demonstrating its commitment to protecting sensitive information and partner trust. This certification reflects the organization's structured risk-based information security management system.
The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.
Dr. Lorenz Studer is known for his pioneering advances in stem cell biology, regenerative medicine, and the development of stem cell-based therapies for neurodegenerative disease.
A new wearable electric-field device has been shown to slow the growth and spread of aggressive breast cancer in preclinical models. The technology uses low-intensity electric fields that interact with cancer cells in a controlled way, reducing tumor growth and increasing immune responses.
The Human Cancer Model Initiative released a compendium of more than 150 organoid models of 25 types of cancer, which are now available to scientists worldwide. These patient-derived organoids provide state-of-the-art research tools for accelerating discovery and developing personalized treatment strategies.
Massey Comprehensive Cancer Center awarded $2.7M K12 grant to support multidisciplinary cancer research and mentor early-stage clinical investigators. The grant aims to optimize participation by high-risk individuals in Virginia.
Researchers developed a framework to integrate AI into hospitals, emphasizing patient care, staff experience, and economic sustainability. The Total Mission Value framework aims to ensure high-quality patient care remains the top priority amidst AI's transformative potential.
A new drug, daraxonrasib, has been identified as a potential treatment for patients with NRAS-driven melanoma. The therapy targets and inhibits RAS protein, which drives cancer growth when mutated. Early results from preclinical models suggest the drug may be effective in treating advanced disease.
Researchers have developed a new drug candidate, SB-0110, that boosts L-dopa's benefits while reducing dyskinetic side effects in animal models of Parkinson’s disease. The compound preserves the gene-activity patterns tied to L-dopa’s benefits while counteracting biological changes associated with dyskinesia.
The symposium marked the hospital's designation as a research-oriented hospital, featuring discussions on collaborative research ecosystems at various levels. Participants engaged in sessions covering future directions, strengthening regional and industry collaborations, and real-world cases of research commercialization.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
Researchers at Technion-Israel Institute of Technology discovered that mature, aged cells can revert into active stem cells that regenerate damaged tissue. This finding challenges the prevailing view on tissue regeneration and implies the possibility of therapies promoting natural healing mechanisms.
A new $250,000 grant will support the development of a novel therapeutic approach for sepsis-associated neurocognitive dysfunction. The treatment aims to protect the brain from inflammation-related damage during and after sepsis, potentially preventing or slowing neurodegeneration and cognitive decline.
A Phase 1/2a clinical study demonstrates long-term survival of transplanted human neural progenitor cells in patients with retinitis pigmentosa, maintaining a favorable safety profile. Visual acuity remained stable, and imaging showed cells remaining present in the subretinal space for at least one year.
The International Society for Stem Cell Research convenes its 2026 Annual Meeting in Montréal, showcasing groundbreaking discoveries and emerging clinical advances. The meeting features nearly 1,300 scientific posters and presentations spanning every area of stem cell research.
The Korea University College of Medicine and UNIST have been selected for the Ministry of Health and Welfare's K-MediST program, aiming to establish a leading model for integrated education and research in medical science and technology. The partnership will create an innovative interdisciplinary hub bridging medicine and engineering.
A new study published in Nature links casdatifan, an investigational HIF-2a inhibitor, to improved clinical outcomes in metastatic clear cell renal cell carcinoma (ccRCC) patients. Deep suppression of serum EPO correlated with higher response rates and longer progression-free survival.
Researchers at the German Center for Infection Research have developed a promising single-dose malaria treatment called SPAP, which targets the malaria parasite through multiple mechanisms. The four-drug combination therapy has shown significant promise in improving malaria treatment and could be a major advancement in sub-Saharan Africa.
The US retains its scientific edge but is losing the race to translate discoveries into cures, warns a new report from Cure Innovation Index. Without immediate renewed investment and policy changes, the US scientific edge will not hold.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
Dr. Jennifer Guida, a renowned researcher and program director, has been appointed as the first director of HonorHealth Research Institute's Division of Institutional Research. She will oversee the institute's clinical trials efforts, providing patients with pioneering treatments based on internal research discoveries.
The Columbia University Irving Medical Center has received a $75 million Clinical and Translational Science Award from the National Institutes of Health. This funding will support translational science at CUIMC, advancing biomedical research from bench to bedside.
Research waste refers to wasting scientific resources due to poor practices, compromising internal and external validity. JMIR Metascience and Research Integrity publishes metascience articles exploring the shortcomings of published literature and investigating its negative impact on real-world outcomes.
A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.
A study found that most persistent viral detection despite effective therapy is due to defective, non-infectious virus copies. The 5'-leader region of the virus is responsible for producing infectious particles, but defects in this area prevent the generation of functional viruses.
Researchers developed a senolytic therapy using dasatinib and quercetin, which preserved disc structure and reduced inflammation, highlighting JUN signaling as a key pathway. This preclinical study provides evidence for a potential therapeutic strategy to slow disease progression in individuals with genetic susceptibility.